Last €19.11 EUR
Change Today +0.455 / 2.44%
Volume 71.1K
IBAB On Other Exchanges
EN Brussels
As of 11:35 AM 02/27/15 All times are local (Market data is delayed by at least 15 minutes).

ion beam applications (IBAB) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/3/15 - €19.45
52 Week Low
03/14/14 - €7.12
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for ION BEAM APPLICATIONS (IBAB)

Related News

No related news articles were found.

ion beam applications (IBAB) Related Businessweek News

No Related Businessweek News Found

ion beam applications (IBAB) Details

Ion Beam Applications SA operates as a cancer diagnostics and treatment equipment company in Belgium, the United States, and internationally. The company develops, manufactures, and supports medical devices and software solutions for cancer treatment by proton beam therapy. It operates in two segments, Proton therapy and Particle accelerators, and Dosimetry. The Proton therapy and Particle accelerators segment develops, fabricates, and services medical and industrial particle accelerators, and proton therapy systems. This segment offers turnkey solutions for the treatment of cancer through the use of proton beams; and a line of cyclotrons used for the production of Positron Emission Tomography or Single Photon Emission Computed Tomography radioisotopes, as well as a line of industrial accelerators for sterilization and ionization. The Dosimetry segment offers measurement and quality assurance instruments for radiotherapy and medical imaging to enable the healthcare professionals to verify that equipment administers the planned dose to the targeted area. The company was founded in 1986 and is headquartered in Louvain-la-Neuve, Belgium.

1,037 Employees
Last Reported Date: 04/12/14
Founded in 1986

ion beam applications (IBAB) Top Compensated Officers

Chief Executive Officer, President, Director ...
Total Annual Compensation: €615.0K
Compensation as of Fiscal Year 2013.

ion beam applications (IBAB) Key Developments

Ion Beam Applications S.A. Signs Contract to Install First Proton Therapy Center in North China

Ion Beam Applications S.A. announced that it has received a significant upfront payment for a new contract with the Zhuozhou Jian Kang Qiao Investment Company Ltd, to establish a proton therapy center in Zhuozhou City, Hebei Province, China. The center will be the first Proton Therapy Center in North China, situated 30 minutes from Beijing and it is expected to treat up to 2,000 patients per year. The contract was signed at the end of 2014 and is worth more than EUR 80 million to IBA including the service contract. This does not impact the company`s guidance for 2014 given at the time of the third quarter results. IBA will equip the new center with its Proteus®PLUS multiroom system including five treatment rooms, four isocentricgantry treatment rooms and a fixedbeam treatment room. IBA will also provide all dosimetry equipment to ensure the safest and fastest commissioning of the center. The contract also includes an operations and maintenance agreement and it is anticipated that patients will be able to access proton therapy treatment at the center at the end of 2016.

IBA and Hewlett Packard Sign Partner Agreement

In 2014, IBA confirmed the company's compliance with the eligibility requirements of the HP PartnerOne affiliate program. Following the qualification procedure, Hewlett Packard appointed IBA as HP Enterprise Business Partner. Within the agreement, Hewlett Packard authorizes IBA to sell its server and network equipment and provide technical support. In addition, IBA Group has the permission to sell the HP software on the territory of the Republic of Belarus. As an HP Enterprise Business Partner, IBA is able to offer its customers a wider range of IT services, as well as software and hardware solutions.

Ion Beam Applications, S.A. Signs Contract to Install Seventh Proteus®One Compact Proton Therapy Solution

Ion Beam Applications SA announced that it has signed a contract with CYCLHAD (a CYCLotron for HADron Therapy) for the installation of its single room proton therapy system Proteus®ONE in Caen, France. The contract includes the delivery of the Proteus®ONE equipment as well as a 15 year maintenance agreement, which together will have a value of between EUR 43 million and EUR 48 million to IBA. The delivery of the equipment is expected to take place in 2017. The contract represents the seventh installation of a Proteus®ONE. The Proteus®ONE system has been developed by IBA to allow more patients globally to access proton therapy. Proteus®ONE is a smaller, less expensive and faster to install solution, encompassing the latest in proton therapy technologies, including Pencil Beam Scanning.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IBAB:BB €19.11 EUR +0.455

IBAB Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Alere Inc $45.47 USD -0.09
Analogic Corp $86.66 USD +0.25
Balchem Corp $58.92 USD -2.40
Quidel Corp $25.68 USD -0.33
Sumitomo Heavy Industries Ltd ¥743.00 JPY -1.00
View Industry Companies

Industry Analysis


Industry Average

Valuation IBAB Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.0x
Price/Book 4.7x
Price/Cash Flow 192.7x
TEV/Sales 1.7x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ION BEAM APPLICATIONS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at